PE20120331A1 - Agentes medicinales unidos a dipeptido - Google Patents

Agentes medicinales unidos a dipeptido

Info

Publication number
PE20120331A1
PE20120331A1 PE2011001237A PE2011001237A PE20120331A1 PE 20120331 A1 PE20120331 A1 PE 20120331A1 PE 2011001237 A PE2011001237 A PE 2011001237A PE 2011001237 A PE2011001237 A PE 2011001237A PE 20120331 A1 PE20120331 A1 PE 20120331A1
Authority
PE
Peru
Prior art keywords
alkyl
group
dipeptide
medicinal agent
breaking
Prior art date
Application number
PE2011001237A
Other languages
English (en)
Spanish (es)
Inventor
Richard D Dimarchi
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PE20120331A1 publication Critical patent/PE20120331A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PE2011001237A 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido PE20120331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13922708P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PE20120331A1 true PE20120331A1 (es) 2012-04-14

Family

ID=42316744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001237A PE20120331A1 (es) 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido

Country Status (13)

Country Link
US (1) US20110237493A1 (enExample)
EP (1) EP2376098A4 (enExample)
JP (2) JP2012512898A (enExample)
KR (1) KR20110114568A (enExample)
CN (1) CN102300580A (enExample)
AU (1) AU2009335711A1 (enExample)
CA (1) CA2747195A1 (enExample)
IL (1) IL213341A0 (enExample)
MX (1) MX2011006527A (enExample)
PE (1) PE20120331A1 (enExample)
RU (1) RU2578591C2 (enExample)
SG (1) SG172290A1 (enExample)
WO (1) WO2010080605A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진물질
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴンアンタゴニスト
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
MX2010012695A (es) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
AU2009274425B2 (en) 2008-06-17 2014-05-15 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
WO2009155258A2 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
EP2376521B1 (en) 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
MX2011006524A (es) 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
CA2796879A1 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation アミド系インスリンプロドラッグ
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
AU2011349331A1 (en) 2010-12-22 2013-07-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン/glp−1レセプタコ−アゴニスト
BR112014007124A2 (pt) * 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
JP6392123B2 (ja) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 糖尿病治療のためのctp系インスリンアナローグ
CN103172726B (zh) * 2011-12-22 2017-06-13 杭州淳泰科技有限公司 胰泌素类似物及其制备方法和用途
EP2820038B1 (en) 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
EP2900255B1 (en) 2012-09-26 2019-01-30 Indiana University Research and Technology Corporation Insulin analog dimers
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
US20230285578A1 (en) * 2020-05-26 2023-09-14 Indiana University Research And Technology Corporation Pth analogs for the treatment of hypoparathyroidism
US20220177538A1 (en) 2020-07-22 2022-06-09 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
US20250268986A1 (en) 2020-11-06 2025-08-28 Novo Nordisk A/S Glp-1 prodrugs and uses thereof
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023217744A1 (en) 2022-05-10 2023-11-16 Novo Nordisk A/S Prodrugs of glp-1 polypeptide and uses thereof
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如glp—1之肽治療劑的口服投與

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) * 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
US4741897A (en) * 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
DE60012721T4 (de) * 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
AUPQ661800A0 (en) * 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
AU2001284697A1 (en) * 2000-08-04 2002-02-18 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
AU2001296962A1 (en) * 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
IL158418A0 (en) * 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
IL161848A0 (en) * 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
JP2006520818A (ja) * 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合glp−1化合物
AU2004228793B2 (en) * 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2621847A1 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability
CN101432025B (zh) * 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
KR20090119876A (ko) * 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진물질
JP2011511778A (ja) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
MX2011006524A (es) * 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.

Also Published As

Publication number Publication date
IL213341A0 (en) 2011-07-31
US20110237493A1 (en) 2011-09-29
MX2011006527A (es) 2011-08-17
KR20110114568A (ko) 2011-10-19
JP2016028082A (ja) 2016-02-25
AU2009335711A1 (en) 2010-07-15
CA2747195A1 (en) 2010-07-15
SG172290A1 (en) 2011-07-28
JP2012512898A (ja) 2012-06-07
WO2010080605A1 (en) 2010-07-15
RU2011129764A (ru) 2013-01-27
RU2578591C2 (ru) 2016-03-27
EP2376098A4 (en) 2014-06-11
EP2376098A1 (en) 2011-10-19
CN102300580A (zh) 2011-12-28

Similar Documents

Publication Publication Date Title
PE20120331A1 (es) Agentes medicinales unidos a dipeptido
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
CY1118243T1 (el) Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα
AR078151A1 (es) Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas.
ECSP099638A (es) Nuevo compuesto de adenina
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
ES2567418T3 (es) Derivados citotóxicos de benzodiazepina
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
DOP2010000046A (es) Compuestos de biciclolactama sustituida
PH12012501881A1 (en) 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PA8759501A1 (es) Formas cristalinas
PE20081834A1 (es) Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
PE20090618A1 (es) Compuestos para el tratamiento de hepatitis c
PE20131034A1 (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional
PE20070171A1 (es) GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa

Legal Events

Date Code Title Description
FC Refusal